Core Viewpoint - Oncotelic Therapeutics, through its subsidiary Sapu Nano, is presenting new findings on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting, emphasizing the significance of tissue concentration in determining organ-specific toxicological outcomes [1][2][3]. Group 1: Presentation Details - The presentation titled "Everolimus Toxicology: Tissue Concentration Effects" will be featured during the Poster Session: ADME/Toxicokinetics I [2]. - Authors of the presentation include W. Chang, N. Chang, T. Hoque, and C. Lee from Sapu Nano, San Diego, CA [2]. - The findings aim to advance understanding of the relationship between tissue-level exposure of everolimus and its toxicological effects, moving beyond traditional plasma pharmacokinetics [2]. Group 2: Significance of Findings - The data presented highlight the importance of tissue pharmacokinetics in determining toxicity profiles for mTOR inhibitors like everolimus [3]. - These findings provide a foundation for developing improved drug delivery strategies, including intravenous and nanoparticle-based formulations that enhance control over biodistribution [3][4]. Group 3: Company Background - Oncotelic Therapeutics, originally formed as OXiGENE, Inc. in 1988, focuses on oncology drug development, particularly for rare pediatric cancers [6]. - The company has a joint venture for Diffuse Intrinsic Pontine Glioma (DIPG) and is also involved in developing treatments for melanoma and Acute Myeloid Leukemia (AML) [6]. - Sapu Nano is dedicated to developing next-generation nanomedicine platforms aimed at improving drug delivery and enhancing therapeutic indices [5].

Core Viewpoint - ARTHEx Biotech has received FDA Fast Track Designation for ATX-01, an investigational RNA therapeutic aimed at treating Myotonic Dystrophy type 1 (DM1), highlighting the urgency and potential of this treatment for a condition with no approved therapies [1][1][1] Company Overview - ARTHEx Biotech is a clinical-stage biotechnology company focused on developing RNA-based therapeutics for neuromuscular disorders [1] - The company is headquartered in Valencia, Spain, and is advancing a pipeline of therapies targeting high unmet needs in muscular, CNS, and cardiac diseases [1] Product Details - ATX-01 is designed to inhibit microRNA-23b (miR-23b), which suppresses muscleblind-like (MBNL) protein expression, addressing the genetic cause of DM1 [1][1] - The dual mechanism of action of ATX-01 increases MBNL production and decreases toxic DMPK mRNA, improving splicing abnormalities associated with DM1 [1][1] Clinical Development - ATX-01 is currently in the Phase I/IIa ArthemiR™ study, with ongoing patient enrollment and data generation [1][1] - The Fast Track Designation allows for more frequent interactions with the FDA to expedite the development and review process for ATX-01 [1][1] Market Context - DM1 is a progressive neuromuscular disorder with no approved disease-modifying therapies, representing a significant unmet medical need [1][1] - The lack of treatment options for DM1 patients emphasizes the importance of ATX-01's development [1][1]